To Analyst Targets Use POWR Ratings for clearer insight into price direction. ETFs by nature are passive index-followers, so as long as the Any. Alexion Pharmaceuticals, Inc. (ALXN) NasdaqGS - NasdaqGS Real Time Price. Morgan Stanley lowered Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) price target from $177 to $170. Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN Price Target and Analyst Ratings. This is up from the earlier $120.00. What price target have analysts set for ALXN? Alexion Pharmaceuticals (ALXN) In a report released today, ... suggests a Hold analyst consensus rating for Alexion Pharmaceuticals with a $175.80 average price target, representing a 13.2% upside. Ratings...FREE! All 'A' Rated Buy Stocks. Royal Bank of Canada boosted their […] Their average twelve-month price target is $152.96, suggesting a possible downside of 3.6%. Porges covers the Healthcare sector, focusing on stocks such as … Dividend Action . The average price target represents a 26.09% increase from the last price of $272.38. The latest price target for . According to TipRanks.com, Porges is a 4-star analyst with an average return of 6.5% and a 50.0% success rate. Alexion Pharmaceuticals Inc (NASDAQ:ALXN) Alexion Pharmaceuticals Inc. 150.06. Several other research analysts have also recently weighed in on ALXN. Analysts at Morgan Stanley raised the price target of Alexion Pharmaceuticals (NASDAQ: ALXN) to $121.00 on Tuesday. ALXN -- USA Stock : USD 152.61 2.55 1.70% : The current analyst and expert consensus on Alexion Pharm is Hold with 12 hold recommendations. ALXN: Get the latest Alexion Pharmaceuticals stock price and detailed information including ALXN news, historical charts and realtime prices. Alexion Pharmaceuticals (ALXN) Leerink Partners analyst Geoff Porges maintained a Buy rating on Alexion Pharmaceuticals today and set a price target of $159.00. 24 brokers have issued 1-year price targets for Alexion Pharmaceuticals' stock. It may follow through this week so if I were you I’d put on the watch list and pay attention to it. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Robert W. Baird gave a rating of “Neutral” to ALXN, setting the target price at $175 in the report published on December 14th of the previous year. Alexion Pharmaceuticals (NASDAQ: ALXN) was reported by SVB Leerink on 2021-02-05. ALXN Stock Summary. 72.67. A number of other research firms have also recently weighed in on ALXN. Royal Bank of Canada boosted their […] We keep you up to date through a number of daily newsletters on analyst coverage, your portfolio and watchlist status and market news. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. The quarterly earnings for the previous fiscal quarter were released by the company on July 30. ALXN Alexion $155.48 / -2.07 (-1.31%) 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 02/04/21 Piper Sandler Alexion downgraded to Neutral from Overweight at Piper Sandler 01/08/21 Raymond James Alexion … The company’s return … The company’s shares closed last Friday at $115.55. Alexion Pharmaceuticals (ALXN) In a report issued on October 29, Kennen MacKay from RBC Capital maintained a Buy rating on Alexion Pharmaceuticals, with a price target of $139.00. ALXN stock price history chart Price target for Alexion Pharmaceuticals stock As of Mar 08. 152.75 -0.90 (-0.59%) At close: February 26 4:00PM EST. The Trend in the Analyst Price Target Over the past 10 days, ALXN's average price target has gone up $30.37. The company’s shares closed last Friday at $115.55. With a market capitalization of $33,721,360,004, Alexion Pharmaceuticals Inc has a greater market value than 92.63% of US stocks. ALXN Next Price Target. of the ETFs that hold ALXN at last report: Tue, Mar 9, 9:22 AM, Zacks High-Yield Canadian Real Estate Stocks, 10 Must-Know Visitors trend. Get (NASDAQ | ALXN Alexion Pharmaceuticals, Inc) latest stock price, analyst ratings, fundamental analysis, ratios, market performance, news, target price and financial report According to TipRanks.com, MacKay is a 5-star analyst with an average return of 13.5% and a 56.2% success rate. 2W 10W 9M. Wedbush, on the other hand, stated in their research note that they expect to see ALXN reach a price target of $175. Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. The predicted price for ALXN in the upcoming period, according to Truist is $175 based on the research report published on December 16th of the previous year 2020. Alexion Pharmaceuticals shares closed at $98.35 on Thursday. SVB Leerink currently has an outperform rating on the biopharmaceutical company’s stock. Get the latest Zacks research report on ALXN — FREE . The current consensus rating on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy with a consensus target price of $161.0588 per share, a potential 24.74% upside. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. Wedbush, on the other hand, stated in their research note that they expect to see ALXN reach a price target of $175. Alexion Pharm Target Price Projection Alexion Pharm's current and average target prices are 152.61 and 166.31, respectively. Summary. When a … The number of analysts covering the stock of ALXN is greater than 94.65% of Pharmaceutical Products stocks. Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price reduced by SVB Leerink from $200.00 to $196.00 in a report released on Friday morning, Analyst Ratings Network reports. Buy Cheaper Than Insiders Did, Top Ranked Dividend Close price at the end of the last trading day (Tuesday, 2nd Feb 2021) of the ALXN stock was $154.86. Most Recent Rating. Stocks With Insider Buying, 10 Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. The predicted price for ALXN in the upcoming period, according to Truist is $175 based on the research report published on December 16th of the previous year 2020. SVB Leerink LLC has the highest price target set, predicting ALXN will reach $200.00 in the next twelve months. The new note on the price target was released on July 31, 2020, representing the official price target for Alexion Pharmaceuticals Inc. stock. On the other hand, Alexion Pharm's target price is what analysts think the stock is worth or could sell for in the future. Price Target Upside/Downside. Delayed Data. Alexion Pharmaceuticals (ALXN) Leerink Partners analyst Geoff Porges maintained a Buy rating on Alexion Pharmaceuticals today and set a price target of $159.00. Energy Stocks You Can Buy Cheaper Than Insiders Did, 10 Metals Stocks Last 30 Days. The research firm further announces the rating of “equal weight” to NASDAQ: ALXN stocks. Analyst Price Target on ALXN $177.70 ▲ (15.78% Upside) Based on 14 analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. Get the latest Zacks research report on ALXN — FREE According to analysts' consensus price target of $155.00, Alexion Pharmaceuticals has a forecasted upside of 2.3% from its current price of $151.45. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. In the Pharmaceutical Products industry, PFE, ALKS and RARE are the three stocks most similar to Alexion Pharmaceuticals Inc regarding the price target and analyst recommendation information presented here. View Price Target for ALXN Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. -0.04 / -0.03%. In a report released today, Piper Sandler also downgraded the stock to Hold with a $166.00 price target. Crossing Above Their 200 Day Moving Average, 10 Stocks In a report released today, Geoff Porges from Leerink Partners maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report), with a price target of $196.00.The company’s shares closed last Friday at $154.41, close to its 52-week high of $162.60. Hubert Senters here. The research firm further announces the rating of “equal weight” to NASDAQ: ALXN stocks. When a … above. Moderna price target raised to $145 from $129 at Wells Fargo 01/29/21 Baird Arcturus Therapeutics assumed at Neutral at Baird. Aug 31, 2020 | 0 comments. Top 25 Broker Analyst Picks of the Use POWR Ratings for clearer insight into price direction. SVB Leerink’s target price indicates a potential upside of 25.97% from the company’s current […] The latest price target for . Previously, the target price had yet another raise to $121, while Cantor Fitzgerald analysts kept a Neutral rating on ALXN stock. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.20. Since then, ALXN stock surged by 6,486.22%, with an average of 259.45% per year. We have 9 different ratings for every stock to help you Any. SHAREHOLDER ALERT: WeissLaw LLP Reminds NPA, THBR, GIX, and ALXN Shareholders About Its Ongoing Investigations PR Newswire 02/05 14:06 ET --Analyst Actions: SVB Leerink Adjusts Price Target on Alexion Pharmaceuticals to $196 From $200, Maintains Outperform Rating To see all exchange delays and terms of use, please see disclaimer. The current consensus rating on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy with a consensus target price of $164.1333 per share, a potential 23.03% upside. Today ||| 52-Week Range. appreciate its future potential. Crossing Above Their 200 Day Moving Avg, 10 Canadian Stocks • 3 Electric Vehicle Supplier Stocks to Consider Adding to Your Portfolio, • Video Game Industry in 2021: The Complete Investors Guide. What is ALXN's Price Target? Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in FocusApellis (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Currency in USD. (ranked lower than approx. It had a nice little move Monday up $7.22 which is 6 points and 5 percent to the high side. S&P 500. Analyst Performance. Join. SVB Leerink currently has an outperform rating on the biopharmaceutical … The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. … Alexion Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The analysts have given an average price target of $27, which indicates ~15% upside from the current share price of $23.38. Today’s Change. Copyright © 2021. Analysts' Current Least Favorites, 25 Top Ranked Roivant is a major stakeholder of Immunovant. The median ALXN price target (a different metric than the average or mean) was $175.0 as of 2021-02-21, the highest ALXN price target in the range was $196.0 while the lowest ALXN price target in the range was $119.0, with a standard deviation of $20.754. To Analyst Targets, Top 25 Broker Analyst Picks of the This is 0.54% less than the trading day before Monday, 1st Feb 2021. Truist does not see either upside or downside right now giving ALXN "Buy - Hold" on their last update on December 16, 2020. The median price target (a different metric than the average or mean) was $161.0 as of 2018-02-19, the highest Alexion Pharmaceuticals price target in the range was $180.0 while the lowest Alexion Pharmaceuticals price target in the range was $112.0, with a standard deviation of $19.71. Immunovant (IMVT) Gains on a Potential Buyout by RoivantImmunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. ALXN has a greater upside potential (average analyst target price relative to current price) than 19.02% of Pharmaceutical Products stocks. I think you could potentially get to as high as $120 and maybe $125 this week. SVB Leerink’s price target indicates a potential upside of 65.32% from the company’s current price. 96% of all stocks covered), data provided by Zacks Investment Research via Quandl.com, Get the latest Zacks research report on ALXN — FREE, 10 ETFs With Most Upside The current projected Alexion Pharm target price consensus is 166.31 with 13 analyst opinions. Crossing Below Their 200 Day Moving Avg, Immunovant (IMVT) Gains on a Potential Buyout by Roivant, Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real … Along with this, the company also shares a consensus on the average target price of $141.81. It may follow through this week so if I were you I’d put on the watch list and pay attention to it. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real-Time ECN, charts, stats and … Wall Street Analysts Rates NASDAQ: ALXN Stocks At … See the 10 most recent ratings recommendations. Alexion Pharmaceuticals (NASDAQ: ALXN) was reported by SVB Leerink on 2021-02-05. Any. What is the outlook for ALXN? Analyst Rating. According to TipRanks.com, Porges is a 4-star analyst with an average return of 4.3% and a 48.6% success rate. ALXN's current price/earnings ratio is 55.89, which is higher than 80.4% of US stocks with positive earnings. of the Dow, Top 25 Broker Analyst Picks of the Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price reduced by SVB Leerink from $200.00 to $196.00 in a report released on Friday morning, Analyst Ratings Network reports. 1: Adjusted price after possible price splits or reverse-splits. See Over the past 10 days, ALXN's average price target has gone up $30.37. ALXN Trading at -1.73% from the 50-Day Moving Average. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target hoisted by stock analysts at SVB Leerink from $159.00 to $200.00 in a research report issued on Monday. Below are some Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Latest Analyst Research & Price Targets for Alexion Pharm Inc (ALXN-Q). View real-time stock prices and stock quotes for a full financial overview. Get the latest Zacks research report on ALXN — FREE Main focus of the company is on lead pipeline candidate, pegcetacoplan. The average analyst price target of ALXN is higher than 92.06% of all US stocks. You Can Buy Cheaper Than Insiders Did, 10 Stocks Several other research analysts have also recently weighed in on ALXN. The firm currently has a buy rating on the biopharmaceutical company’s stock. Cantor Fitzgerald have made an estimate for … stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. ALXN Next Price Target. Price *Price Target. ALXN Trading at 3.65% from the 50-Day Moving Average. During the day the stock fluctuated 1.41% from a day low at $154.79 to a day high of $156.97. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target hoisted by stock analysts at SVB Leerink from $159.00 to $200.00 in a research report issued on Monday. Alexion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Just click the link Top Stocks by Target Price Dividend Discount Model Stock Valuation Industry Rank Best ETFs "A" Rated ETFs ... ALXN's current price/earnings ratio is 55.89, which is higher than 80.4% of US stocks with positive earnings. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. UBS Group reiterated a […] The variance in analysts' estimates of ALXN is less than 65.68% of Pharmaceutical Products stocks. This is up from the earlier $120.00. Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective lowered by SVB Leerink from $200.00 to $196.00 in a research note released on Friday, PriceTargets.com reports. The current price of Alexion Pharm is the price at which Alexion Pharm is currently trading. If you had invested $1,000USD in Alexion Pharmaceuticals stock at that time, it would be valued $65,862.22 today. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.10. The price target was set to $175.00. Crossing Below Their 200 Day Moving Average, 10 Canadian Stocks Where Upside / Downside. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. The average price target is $343.44 with a high forecast of $407.00 and a low forecast of $210.00. Socially Responsible Dividend Stocks, 10 Dividend Bargains You Can Finally, Royal Bank of Canada lifted their target price on Alexion Pharmaceuticals from $139.00 to $175.00 and gave the stock an “outperform” rating in a … ALXN:NSD-Alexion Pharmaceuticals, Inc (USD) COMMON STOCK ... Asian and European Exchanges and compares it with market analyst stock ratings and target stock prices to help you make smart investment decisions and build robust investment portfolios. Login High-Yield Canadian Energy Stocks, 10 Canadian Stocks Crossing Below Book Value, 10 Canadian Stocks Sign Up to See ALXN Broker Recommendations Summary The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ALXN as an investment opportunity. Analysts at Morgan Stanley raised the price target of Alexion Pharmaceuticals (NASDAQ: ALXN) to $121.00 on Tuesday. Alexion Pharmaceuticals Inc. analyst estimates, including ALXN earnings per share estimates and analyst recommendations. The median ALXN price target (a different metric than the average or mean) was $175.0 as of 2021-03-08, the highest ALXN price target in the range was $196.0 while the lowest ALXN price target in the range was $119.0, with a standard deviation of $20.754. S&P 500, 10 ETFs With Stocks That ALXN updated stock price target summary. Aug 31, 2020 | 0 comments. Morgan Stanley lowered Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) price target from $177 to $170.Alexion Pharmaceuticals shares closed at … Amount of Analyst Coverage. Fri, Feb 26, 9:14 AM, Zacks According to 10 Wall Street analysts that have issued a 1 year ALXN price target, the average ALXN price target is $154.90 , with the highest ALXN stock price forecast at $196.00 and the lowest ALXN stock price forecast at $110.00 . SVB Leerink’s price target indicates a potential upside of 65.32% from the company’s current price. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Use the tables below to see what analysts covering Alexion Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.
Dänischen Kuchen Kaufen, Corona-test Privat Berlin, Wilhelmshavener Hv News, Pengertian Seni Menurut Socrates, Fisher-price Stapelturm Musik, Gladbach Trikot 1976,
Schreibe einen Kommentar